Producing Integrase Minus Lentivirus for Transient Expression of the Desired Protein and Reduced Side Effects of the Virus in Gene Therapy

Document Type : Original Article (s)

Authors

1 PhD Student, Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran

2 MSc Student, Department of Genetics and Molecular Biology, School of Medicine AND Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

3 Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 PhD Student, Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

5 Associate Professor, Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

6 Professor, Department of Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

7 Assistant Professor, Pediatric Inherited Diseases Research Center, Research Institute for Primordial Prevention of Non-communicable Disease AND Department of Genetics and Molecular Biology, School of Medicine, Isfahan University Of Medical Sciences, Isfahan, Iran

Abstract

Background: Lentiviral vectors are very efficient tools for gene therapy. But, proviral integration make their use dangerous; therefore, the safer integration deficient lentiviral vectors (IDLVs) can be produced through the use of integrase gene mutations that specifically prevent proviral integration. This study was launched to design and construct a second generation integration deficient lentiviral vector suitable for transient gene targeting with viral vector.Methods: Applying the site directed mutagenesis strategy through the overlap polymerase chain reaction technique, a missense mutation (D64V) was induced in the catalytic domain of the integrase gene in the psPAX2 (packaging) plasmid and was verified using DNA sequencing. The HEK293T cell line was transfected using the psPAX2 plasmid (native and integrase minus), pLOX (transfer plasmid) and PMD2G (envelope plasmid). The viruses were harvested and the HEK293T cell line was transuded. The levels of expression of the green fluorescent protein (GFP) reporter gene were monitored in the cells transduced with either native or defective virus for ten days.Findings: We observed a slight slope of decrease in the number of GFP-positive cells transduced with native viruses during the period. In contrast, in the case of defective viruses, a significant decrease in the number of GFP positive cells was noted.Conclusion: In this study, the integrase-minus psPAX2 was constructed and confirmed. The results demonstrate that the IDLV can provide a useful tool for efficient transient gene expression and can help to avoid disadvantages of gene targeting using the native virus.

Keywords

References

  1. Joglekar AV, Hollis RP, Kuftinec G, Senadheera S, Chan R, Kohn DB. Integrase-defective lentiviral vectors as a delivery platform for targeted modification of adenosine deaminase locus. Mol Ther 2013; 21(9): 1705-17.
  2. Wiznerowicz M, Trono D. Harnessing HIV for therapy, basic research and biotechnology. Trends Biotechnol 2005; 23(1): 42-7.
  3. Hematti P, Hong BK, Ferguson C, Adler R, Hanawa H, Sellers S, et al. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol 2004; 2(12): e423.
  4. Hacein-Bey-Abina S, von KC, Schmidt M, Le DF, Wulffraat N, McIntyre E, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348(3): 255-6.
  5. Vargas J, Gusella GL, Najfeld V, Klotman ME, Cara A. Novel integrase-defective lentiviral episomal vectors for gene transfer. Hum Gene Ther 2004; 15(4): 361-72.
  6. Cara A, Reitz MS. New insight on the role of extrachromosomal retroviral DNA. Leukemia 1997; 11(9): 1395-9.
  7. Michelini Z, Negri D, Cara A. Integrase defective, nonintegrating lentiviral vectors. Methods Mol Biol 2010; 614: 101-10.
  8. Saenz DT, Loewen N, Peretz M, Whitwam T, Barraza R, Howell KG, et al. Unintegrated lentivirus DNA persistence and accessibility to expression in nondividing cells: analysis with class I integrase mutants. J Virol 2004; 78(6): 2906-20.
  9. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272(5259): 263-7.
  10. Pacchia AL, Adelson ME, Kaul M, Ron Y, Dougherty JP. An inducible packaging cell system for safe, efficient lentiviral vector production in the absence of HIV-1 accessory proteins. Virology 2001; 282(1): 77-86.
  11. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15(9): 871-5.
  12. Tiscornia G, Singer O, Verma IM. Production and purification of lentiviral vectors. Nat Protoc 2006; 1(1): 241-5.
  13. McTaggart S, Al-Rubeai M. Retroviral vectors for human gene delivery. Biotechnol Adv 2002; 20(1): 1-31.
  14. Pluta K, Kacprzak MM. Use of HIV as a gene transfer vector. Acta Biochim Pol 2009; 56(4): 531-95.
  15. Morris KV, Rossi JJ. Lentiviral-mediated delivery of siRNAs for antiviral therapy. Gene Ther 2006; 13(6): 553-8.
  16. Duarte S, Carle G, Faneca H, de Lima MC, Pierrefite-Carle V. Suicide gene therapy in cancer: where do we stand now? Cancer Lett 2012; 324(2): 160-70.
  17. Wanisch K, Yanez-Munoz RJ. Integration-deficient lentiviral vectors: a slow coming of age. Mol Ther 2009; 17(8): 1316-32.
  18. Rivella S, Callegari JA, May C, Tan CW, Sadelain M. The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites. J Virol 2000; 74(10): 4679-87.
  19. Farrell CM, West AG, Felsenfeld G. Conserved CTCF insulator elements flank the mouse and human beta-globin loci. Mol Cell Biol 2002; 22(11): 3820-31.
  20. Gaur M, Leavitt AD. Mutations in the human immunodeficiency virus type 1 integrase D,D(35)E motif do not eliminate provirus formation. J Virol 1998; 72(6): 4678-85.
  21. Banasik MB, McCray PB. Integrase-defective lentiviral vectors: progress and applications. Gene Ther 2010; 17(2): 150-7.
  22. Farazmandfar T, Khanahmad SH, Haghshenas MR, Janbabai G, Azadeh H, Mansour SN. Use of integrase-minus lentiviral vector for transient expression. Cell J 2012; 14(2): 76-81.
  23. Yu SS, Dan K, Chono H, Chatani E, Mineno J, Kato I. Transient gene expression mediated by integrase-defective retroviral vectors. Biochem Biophys Res Commun 2008; 368(4): 942-7.
Journal of Isfahan Medical School
Volume 33, Issue 326 - Serial Number 326
January and February 2015
Pages 305-315

Files

History

  • Receive Date: 08 December 2014
  • Revise Date: 23 May 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics